The American journal Medicine, specialising in research articles on medical scientific disciplines and subspecialties, has recently published the clinical case of Repigment12.
In the article, authored by Dr. Matteo Bordignon (dermatologist specialising in vitiligo), Jordi Segura (R&D Director of Bella Aurora), Sergi Hernández (Fundamental Research Manager of Bella Aurora) and Marta Bajona (Medical Advisor of Bella Aurora) among others, the results of studies conducted on the use of MIA inhibitors for the treatment of hypopigmentation are presented.
The scientific journal Medicine, through a committee of experts, certifies the scientific, technical, and ethical validity of the studies conducted and ensures compliance with high quality standards. Furthermore, the journal endorses the clinical case presented by Bella Aurora laboratories and Dr. Matteo Bordignon, which demonstrates the efficacy of Repigment12.
Repigment12 is the result of more than 4 years of collaboration between Bella Aurora laboratories and Dr. Matteo Bordignon, an Italian dermatologist specialising in vitiligo. In May 2021, it was launched on the market as the first cosmetic treatment for Bella Aurora's white spots.
To read the full scientific paper, click here.
